Travere Therapeutics (TVTX) CCO gets 69,640 options and sells shares for taxes

Rhea-AI Filing Summary

Travere Therapeutics, Inc. Chief Commercial Officer Peter Heerma reported equity transactions in company stock. On January 31, 2026, he acquired 26,120 shares of common stock at $0 per share in connection with restricted stock units, bringing his direct holdings to 139,133 shares.

That same day, he received an employee stock option grant for 69,640 shares at an exercise price of $33.095 per share, vesting over four years. On February 3, 2026, he sold 7,310 shares at $32.12 per share to cover tax withholding owed on vested restricted stock units. The sale was executed under a mandatory "sell to cover" arrangement and is not described as a discretionary trade. After this sale, he directly held 131,823 shares of Travere common stock.

Insider Trade Summary

Net Seller: 7,310 shares ($234,797)

Net Sell 3 txns

Insider Heerma Peter

Role CHIEF COMMERCIAL OFFICER

Sold 7,310 shs ($235K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,310	$32.12	$235K
Grant/Award	Employee stock option (right to buy)	69,640	$0.00	--
Grant/Award	Common Stock	26,120	$0.00	--

Holdings After Transaction: Common Stock — 131,823 shares (Direct); Employee stock option (right to buy) — 69,640 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heerma Peter

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, SUITE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF COMMERCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		A(1)		26,120	A	$0	139,133	D
Common Stock	02/03/2026		S(2)		7,310	D	$32.12	131,823	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$33.095	01/31/2026		A		69,640		(3)	01/31/2036	Common Stock	69,640	$0	69,640	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

2. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

3. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Travere Therapeutics (TVTX) report for Peter Heerma?

Travere Therapeutics reported that Chief Commercial Officer Peter Heerma received 26,120 common shares and an option for 69,640 shares, and sold 7,310 shares to satisfy tax withholding obligations tied to vested restricted stock units.

How many Travere Therapeutics (TVTX) shares did the CCO sell and at what price?

Chief Commercial Officer Peter Heerma sold 7,310 shares of Travere Therapeutics common stock at $32.12 per share. The sale was specifically to cover tax withholding obligations from vested restricted stock units under a mandated "sell to cover" arrangement.

Were the Travere Therapeutics (TVTX) insider sales by Peter Heerma discretionary trades?

The reported sale of 7,310 shares by Peter Heerma was not a discretionary trade. It was mandated to cover tax withholding on vested restricted stock units through a broker-directed "sell to cover" transaction chosen under the company’s equity incentive plans.

What new stock option grant did Travere Therapeutics (TVTX) give to its CCO?

Travere Therapeutics granted its Chief Commercial Officer an employee stock option for 69,640 shares of common stock at an exercise price of $33.095 per share, vesting over four years with one-fourth after one year and the rest in monthly installments.

How many Travere Therapeutics (TVTX) shares does Peter Heerma hold after these transactions?

Following the reported transactions, Chief Commercial Officer Peter Heerma directly holds 131,823 shares of Travere Therapeutics common stock. He also holds an option covering 69,640 additional shares, which vest over time based on the grant’s vesting schedule.

What is the vesting schedule for Peter Heerma’s new Travere Therapeutics stock option?

The 69,640-share stock option grant vests with one-fourth becoming exercisable on the first anniversary of the grant date. The remaining shares then vest in 36 equal monthly installments until fully vested, subject to continued service conditions.